Skip to main content
Clinical Trials/NCT06551805
NCT06551805
Recruiting
Not Applicable

Clinical Research Protocol of Ferumoxytol for Magnetic Resonance Enhancement Imaging in Patients With Atherosclerosis.

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1 site in 1 country100 target enrollmentAugust 12, 2024

Overview

Phase
Not Applicable
Intervention
Safety assessment of Ferumoxytol.
Conditions
Atherosclerosis
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Enrollment
100
Locations
1
Primary Endpoint
Ferumoxytol demonstrates a favorable safety profile in human subjects.
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

We are preparing to initiate a clinical trial involving Ferumoxytol for magnetic resonance-enhanced imaging in patients with atherosclerosis. The aim of this study is to assess the safety and effectiveness of Ferumoxytol for magnetic resonance angiography in patients with atherosclerosis.

Detailed Description

In this study, the safety of Ferumoxytol as an MR imaging contrast agent will be assessed by monitoring vital signs and laboratory parameters such as complete blood count, urinalysis, and liver and kidney function tests before and after administration of Ferumoxytol. Following the injection, all patients will undergo two MRI scans at different time intervals, ranging from 0 to 15 hours and from 24 to 48 hours. Within one week prior to the injection, patients will undergo standard laboratory tests as part of their routine clinical assessment, and the pre-administration lab results will be documented. This study will prospectively enroll patients with atherosclerosis, and Ferumoxytol-enhanced MRA imaging will be performed on all patients to investigate the diagnostic utility of Ferumoxytol as an MR imaging contrast agent.

Registry
clinicaltrials.gov
Start Date
August 12, 2024
End Date
December 30, 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Safety assessment and the diagnostic value of Ferumoxytol.

Drug Name: Ferumoxytol Dosage Form: Injection Dosage: 3 mg/kg Administration Frequency: Single intravenous injection

Intervention: Safety assessment of Ferumoxytol.

Safety assessment and the diagnostic value of Ferumoxytol.

Drug Name: Ferumoxytol Dosage Form: Injection Dosage: 3 mg/kg Administration Frequency: Single intravenous injection

Intervention: Assessment of the diagnostic value of Ferumoxytol for MR angiography.

Outcomes

Primary Outcomes

Ferumoxytol demonstrates a favorable safety profile in human subjects.

Time Frame: 2023.10-2026.12

safe

Ferumoxytol exhibits diagnostic efficacy for MR angiography.

Time Frame: 2023.10-2026.12

diagnostic efficacy

Study Sites (1)

Loading locations...

Similar Trials